CLX Medical, Inc. (www.clxinvestments.com) is focused on the launch of innovative rapid medical diagnostic testing products in the United States and worldwide markets. The Company holds a 51% equity interest in Zonda, Inc., which has developed a rapid diagnostic test for chlamydia and is preparing to initiate clinical trials as part of the process to achieve FDA clearance for the product. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX Medical, Inc.
c/o CLX Medical, Inc.
29970 Technology Drive
Suite 203
Murrieta, CA 92563
http://www.clxinvestments.com/

Phone: 951-677-6735
Fax: 951-677-6573
E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

CLX Medical, Inc. Announces the Planned Acquisition of the ThyroTest(R) Rapid Screening Device

Market Wire "US Press Releases "

MURRIETA, CA -- (MARKET WIRE) -- 08/11/08 -- CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the company has entered into a letter of intent with ThyroTec, LLC to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX will now proceed toward a definitive agreement for the acquisition of ThyroTest, which would be positioned in a wholly owned subsidiary of CLX Medical.

The last phase of CLX's analysis and research process on the ThyroTest® product includes an in-depth analysis of competitive strengths and is part of an ongoing study of the product by a clinical laboratory affiliated with a major U.S. university. Data from the study is expected to be made available in the near term.

In addition to the acquisition of ThyroTest®, CLX Medical expects to enter into a co-development deal with ThyroTec, LLC to secure worldwide sales and marketing rights for 2 additional products in the medical diagnostic testing market.

"Our analysis of the potential market for ThyroTest indicates that it is much larger than the current estimated instance of hypothyroidism in the U.S.," stated Vera Leonard, chief executive officer of CLX Medical. "The wide range of symptoms, most of them very common in today's society, opens what we view to be a significant opportunity for a screening device like ThyroTest® that is CLIA waived and therefore allowed to be used in a wide variety of testing venues. We also believe that ThyroTest® is significantly superior to competitive products, and our marketing strategy for the product will include providing data that supports this contention."

CLX anticipates that Ms. Leonard will be providing additional follow-up information on ThyroTest®, as well as the opportunity presented by this product and the acquisition in the coming days.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc., which has developed rapid point of care tests for medical and non-medical markets, and CLX recently announced a letter of intent to acquire another rapid diagnostic device for the medical market. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

About ThyroTest®

ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctor's offices in the U.S., as well as in any non-waived laboratory. The simple rapid diagnostic test is a qualitative measurement that allows physicians to screen adult patients for hypothyroidism in approximately ten minutes with a whole blood sample.

Hypothyroidism develops when the thyroid gland does not produce enough thyroid hormone to properly regulate the body's metabolism. A lack of thyroid hormone affects many body systems. The incidence of hypothyroidism tends to increase with age, with older people, especially women, at highest risk. Common symptoms include weight gain, fatigue, mood swings, weakness, dry and coarse skin and hair, hair loss, depression, decreased libido, trouble swallowing, increased cholesterol, heavy or irregular periods or trouble getting pregnant.

Approximately 120 million thyroid-related lab tests are performed in the United States each year. At an estimated average cost of $40 per test, the U.S. market is currently valued at nearly $5 billion. Approximately 45 million of those tests are conducted in order to diagnose thyroid dysfunction. CLX believes that ThyroTest® is an appropriate, cost-effective first-step for those 45 million diagnostic TSH tests. This current U.S. market opportunity is amplified by the CLIA waived status, which makes the opportunity to meet American Thyroid Association recommendations for screening every individual at age 35 and every five years thereafter a reality.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:
Gemini Financial Communications, Inc.
A. Beyer
951-677-8073
Email Contact

9 Grand through it so far... not great, but not terrible.

what u hoping for i havent seen it up after all the PRs from last week
i am only in $1000

lots of volume today and 0005's are selling like crazy

Hi, I just got in these recently on their latest news and i hope that they close the deal real quick so i can make some money..

November 19, 2008 - 11:34 AM EST


CLX Medical, Inc. Updates Status of ThyroTest(R) Close
MURRIETA, CA -- (Marketwire) -- 11/19/08 -- CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today updated the status of the pending close of the company\'s acquisition of ThyroTest® through the issuance of preferred stock and a note in the amount of $750,000.

To close the transaction, an escrow is being established, into which the ThyroTest® technology, the $750,000 note and the 750,000 shares of Series C Preferred Shares will be deposited. The opening of the escrow will be considered the closing, and the company had expected to have established the escrow and deposited the note and the shares by November 14, 2008.

\"The escrow has been opened, and the documents have been approved in form by both parties to the agreement and are now being transferred to the escrow holder,\" stated Vera Leonard, chief executive officer of CLX Medical. \"The process is moving forward, and we expect to have the close completed by the end of this week.\"

ThyroTest® is a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors\' offices in the U.S., as well as in any non-waived laboratory.

CLX Medical entered into a definitive agreement with ThyroTec, LLC, the developer of the ThyroTest® device, on September 8, 2008 and subsequently entered into an amendment to the definitive agreement. The amendment provided that the transaction could be closed through the issuance to ThyroTec of Series C Convertible Preferred Shares of CLX Medical and a note in the amount of $750,000 at 6% interest for a term of 30 months, secured by the assets of the corporation. During the period of the note or until the principal is paid in full, CLX agrees to pay to ThyroTec a royalty of 10% of net sales of the ThyroTest® product.